Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-02

AUTHORS

L. K. Webster, Martha E. Linsenmeyer, Danny Rischin, Maureen E. Urch, David M. Woodcock, Michael J. Millward

ABSTRACT

Docetaxel (Taxotere, Rhone-Poulenc Rorer) and etoposide are water-insoluble drugs formulated with polysorbate 80 for intravenous administration. We have previously reported that surfactants, including polysorbate 80 and Cremophor EL, can reverse the multidrug resistance (MDR) phenotype in an experimental system and that plasma Cremophor EL concentrations measured following a 3-h infusion of paclitaxel were > or = 1 microliter/ml, sufficient to modulate MDR in vitro. The purpose of this study was to measure polysorbate 80 plasma concentrations in patients following intravenous administration of etoposide or docetaxel using a bioassay in which MDR-expressing cells are incubated with daunorubicin (DNR) plus 50/50 growth medium/plasma and equilibrium intracellular DNR fluorescence is measured by flow cytometry. In vitro experiments show maximal reversal of MDR at concentrations of 1.0-2.0 microliters/ml and 50% reversal at 0.2-0.3 microliter/ml. Patients received docetaxel at 75 mg/m2 (five patients) or 100 mg/m2 (four patients) (total dose 125-178 mg, containing 3.12-4.45 ml polysorbate 80) over 60 min. The median end-infusion polysorbate 80 concentration was 0.1 microliter/ml (range 0.07-0.41 microliter/ml). Only one patient had a level of > 0.2 microliter/ml. Five patients received intravenous etoposide at 120 mg/m2 over 45-120 min (total dose 180-250 mg, containing 0.67-0.93 ml polysorbate 80). In the end-infusion plasma sample, polysorbate 80 was not detectable (< 0.06 microliter/ml) in any patient. Plasma polysorbate 80 levels following an intravenous infusion of 120 mg/m2 etoposide or of docetaxel at doses used in Phase II trials, are insufficient to show modulation of MDR in vitro. More... »

PAGES

557-560

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002800050615

DOI

http://dx.doi.org/10.1007/s002800050615

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045464009

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9118471


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Paclitaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polysorbates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surface-Active Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Research, Peter MacCallum Cancer Institute, Locked Bag No. 1, A\u2019Beckett Street, Melbourne, VIC, Australia 3000 Tel.+61-3-9656-1275; Fax+61-3-9656-1411; E-mail lwebster@petermac.unimelb.edu.au, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Webster", 
        "givenName": "L. K.", 
        "id": "sg:person.01062315554.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062315554.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Research, Peter MacCallum Cancer Institute, Locked Bag No. 1, A\u2019Beckett Street, Melbourne, VIC, Australia 3000 Tel.+61-3-9656-1275; Fax+61-3-9656-1411; E-mail lwebster@petermac.unimelb.edu.au, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Linsenmeyer", 
        "givenName": "Martha E.", 
        "id": "sg:person.0776211666.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776211666.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria, Australia 3002, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rischin", 
        "givenName": "Danny", 
        "id": "sg:person.01270354677.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270354677.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria, Australia 3002, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Urch", 
        "givenName": "Maureen E.", 
        "id": "sg:person.01164010625.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164010625.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Research, Peter MacCallum Cancer Institute, Locked Bag No. 1, A\u2019Beckett Street, Melbourne, VIC, Australia 3000 Tel.+61-3-9656-1275; Fax+61-3-9656-1411; E-mail lwebster@petermac.unimelb.edu.au, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woodcock", 
        "givenName": "David M.", 
        "id": "sg:person.01261320737.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261320737.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria, Australia 3002, AU"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Millward", 
        "givenName": "Michael J.", 
        "id": "sg:person.01075643161.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075643161.66"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1997-02", 
    "datePublishedReg": "1997-02-01", 
    "description": "Docetaxel (Taxotere, Rhone-Poulenc Rorer) and etoposide are water-insoluble drugs formulated with polysorbate 80 for intravenous administration. We have previously reported that surfactants, including polysorbate 80 and Cremophor EL, can reverse the multidrug resistance (MDR) phenotype in an experimental system and that plasma Cremophor EL concentrations measured following a 3-h infusion of paclitaxel were > or = 1 microliter/ml, sufficient to modulate MDR in vitro. The purpose of this study was to measure polysorbate 80 plasma concentrations in patients following intravenous administration of etoposide or docetaxel using a bioassay in which MDR-expressing cells are incubated with daunorubicin (DNR) plus 50/50 growth medium/plasma and equilibrium intracellular DNR fluorescence is measured by flow cytometry. In vitro experiments show maximal reversal of MDR at concentrations of 1.0-2.0 microliters/ml and 50% reversal at 0.2-0.3 microliter/ml. Patients received docetaxel at 75 mg/m2 (five patients) or 100 mg/m2 (four patients) (total dose 125-178 mg, containing 3.12-4.45 ml polysorbate 80) over 60 min. The median end-infusion polysorbate 80 concentration was 0.1 microliter/ml (range 0.07-0.41 microliter/ml). Only one patient had a level of > 0.2 microliter/ml. Five patients received intravenous etoposide at 120 mg/m2 over 45-120 min (total dose 180-250 mg, containing 0.67-0.93 ml polysorbate 80). In the end-infusion plasma sample, polysorbate 80 was not detectable (< 0.06 microliter/ml) in any patient. Plasma polysorbate 80 levels following an intravenous infusion of 120 mg/m2 etoposide or of docetaxel at doses used in Phase II trials, are insufficient to show modulation of MDR in vitro.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s002800050615", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "name": "Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide", 
    "pagination": "557-560", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d890957c9e4fb485098af71f67322cdff264805a41d9629801ecfcdd987f37f0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9118471"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002800050615"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045464009"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002800050615", 
      "https://app.dimensions.ai/details/publication/pub.1045464009"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs002800050615"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800050615'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800050615'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800050615'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800050615'


 

This table displays all metadata directly associated to this object as RDF triples.

153 TRIPLES      20 PREDICATES      41 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002800050615 schema:about N1643cdcca09d4292b2c1974f0a3bad4e
2 N2cb048acb9be494984c844c6f8fc91e8
3 N32cf489fc71b403baf23ddd3cab4a14e
4 N3bf23472889e4aa8b89950d41fe3880c
5 N3f50015c2dea47949de5a0ad1ca2682c
6 N6246e84307b240f59563f302195a1c4c
7 N83e314c25eb04526aa8974fb9e2d3a31
8 N977a207aded94a8e9a4ffd5e7c4a99ef
9 Ne314bd280ab843408688a1e08d27fe8f
10 Nf37b1ce49e7648379bf9129005a26100
11 Nf7c8405b83fc4d1ebe1479295c30af82
12 Nfb37aad2fecd492b861864f926baf02f
13 anzsrc-for:11
14 anzsrc-for:1115
15 schema:author N6e70b3aba8474f0da37084102219ce53
16 schema:datePublished 1997-02
17 schema:datePublishedReg 1997-02-01
18 schema:description Docetaxel (Taxotere, Rhone-Poulenc Rorer) and etoposide are water-insoluble drugs formulated with polysorbate 80 for intravenous administration. We have previously reported that surfactants, including polysorbate 80 and Cremophor EL, can reverse the multidrug resistance (MDR) phenotype in an experimental system and that plasma Cremophor EL concentrations measured following a 3-h infusion of paclitaxel were > or = 1 microliter/ml, sufficient to modulate MDR in vitro. The purpose of this study was to measure polysorbate 80 plasma concentrations in patients following intravenous administration of etoposide or docetaxel using a bioassay in which MDR-expressing cells are incubated with daunorubicin (DNR) plus 50/50 growth medium/plasma and equilibrium intracellular DNR fluorescence is measured by flow cytometry. In vitro experiments show maximal reversal of MDR at concentrations of 1.0-2.0 microliters/ml and 50% reversal at 0.2-0.3 microliter/ml. Patients received docetaxel at 75 mg/m2 (five patients) or 100 mg/m2 (four patients) (total dose 125-178 mg, containing 3.12-4.45 ml polysorbate 80) over 60 min. The median end-infusion polysorbate 80 concentration was 0.1 microliter/ml (range 0.07-0.41 microliter/ml). Only one patient had a level of > 0.2 microliter/ml. Five patients received intravenous etoposide at 120 mg/m2 over 45-120 min (total dose 180-250 mg, containing 0.67-0.93 ml polysorbate 80). In the end-infusion plasma sample, polysorbate 80 was not detectable (< 0.06 microliter/ml) in any patient. Plasma polysorbate 80 levels following an intravenous infusion of 120 mg/m2 etoposide or of docetaxel at doses used in Phase II trials, are insufficient to show modulation of MDR in vitro.
19 schema:genre research_article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf N6f67ed3133aa4f31a40137c701ea60db
23 Nd88a36d701e1471da5dc4ab14cd18f43
24 sg:journal.1088364
25 schema:name Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide
26 schema:pagination 557-560
27 schema:productId N3ee6836d02894df89af133f31e765b1a
28 N6289dee9e603446f90688364b4e98d7a
29 Nacb812a5795b40ca9341f40b73756a67
30 Nb27f6c97d03f43d6a5b124b9148700ca
31 Nd3c05589b5e0484faf98763aa24ce9a1
32 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045464009
33 https://doi.org/10.1007/s002800050615
34 schema:sdDatePublished 2019-04-10T17:32
35 schema:sdLicense https://scigraph.springernature.com/explorer/license/
36 schema:sdPublisher N43ff807213544365b99adc1b9edd471d
37 schema:url http://link.springer.com/10.1007%2Fs002800050615
38 sgo:license sg:explorer/license/
39 sgo:sdDataset articles
40 rdf:type schema:ScholarlyArticle
41 N1643cdcca09d4292b2c1974f0a3bad4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
42 schema:name Aged
43 rdf:type schema:DefinedTerm
44 N1bdc6fe8511b4770951524bbfc3bfc49 rdf:first sg:person.01270354677.50
45 rdf:rest N47ca4d36f248471c8b584d031dc2f141
46 N2cb048acb9be494984c844c6f8fc91e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
47 schema:name Antineoplastic Agents, Phytogenic
48 rdf:type schema:DefinedTerm
49 N32cf489fc71b403baf23ddd3cab4a14e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Polysorbates
51 rdf:type schema:DefinedTerm
52 N3bf23472889e4aa8b89950d41fe3880c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Taxoids
54 rdf:type schema:DefinedTerm
55 N3ee6836d02894df89af133f31e765b1a schema:name nlm_unique_id
56 schema:value 7806519
57 rdf:type schema:PropertyValue
58 N3f50015c2dea47949de5a0ad1ca2682c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Middle Aged
60 rdf:type schema:DefinedTerm
61 N43ff807213544365b99adc1b9edd471d schema:name Springer Nature - SN SciGraph project
62 rdf:type schema:Organization
63 N448e800251894640838720696451eabf rdf:first sg:person.01261320737.46
64 rdf:rest Nabc4437859f0419690f8fdb7e5bbe6a2
65 N47ca4d36f248471c8b584d031dc2f141 rdf:first sg:person.01164010625.72
66 rdf:rest N448e800251894640838720696451eabf
67 N6246e84307b240f59563f302195a1c4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Male
69 rdf:type schema:DefinedTerm
70 N6289dee9e603446f90688364b4e98d7a schema:name doi
71 schema:value 10.1007/s002800050615
72 rdf:type schema:PropertyValue
73 N6e70b3aba8474f0da37084102219ce53 rdf:first sg:person.01062315554.40
74 rdf:rest Ne66e43387e804087be2d19da97f83b06
75 N6f67ed3133aa4f31a40137c701ea60db schema:volumeNumber 39
76 rdf:type schema:PublicationVolume
77 N83e314c25eb04526aa8974fb9e2d3a31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Neoplasms
79 rdf:type schema:DefinedTerm
80 N977a207aded94a8e9a4ffd5e7c4a99ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Etoposide
82 rdf:type schema:DefinedTerm
83 Nabc4437859f0419690f8fdb7e5bbe6a2 rdf:first sg:person.01075643161.66
84 rdf:rest rdf:nil
85 Nacb812a5795b40ca9341f40b73756a67 schema:name readcube_id
86 schema:value d890957c9e4fb485098af71f67322cdff264805a41d9629801ecfcdd987f37f0
87 rdf:type schema:PropertyValue
88 Nb27f6c97d03f43d6a5b124b9148700ca schema:name dimensions_id
89 schema:value pub.1045464009
90 rdf:type schema:PropertyValue
91 Nd3c05589b5e0484faf98763aa24ce9a1 schema:name pubmed_id
92 schema:value 9118471
93 rdf:type schema:PropertyValue
94 Nd88a36d701e1471da5dc4ab14cd18f43 schema:issueNumber 6
95 rdf:type schema:PublicationIssue
96 Ne314bd280ab843408688a1e08d27fe8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Paclitaxel
98 rdf:type schema:DefinedTerm
99 Ne66e43387e804087be2d19da97f83b06 rdf:first sg:person.0776211666.91
100 rdf:rest N1bdc6fe8511b4770951524bbfc3bfc49
101 Nf37b1ce49e7648379bf9129005a26100 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Female
103 rdf:type schema:DefinedTerm
104 Nf7c8405b83fc4d1ebe1479295c30af82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Surface-Active Agents
106 rdf:type schema:DefinedTerm
107 Nfb37aad2fecd492b861864f926baf02f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Humans
109 rdf:type schema:DefinedTerm
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
114 schema:name Pharmacology and Pharmaceutical Sciences
115 rdf:type schema:DefinedTerm
116 sg:journal.1088364 schema:issn 0344-5704
117 1432-0843
118 schema:name Cancer Chemotherapy and Pharmacology
119 rdf:type schema:Periodical
120 sg:person.01062315554.40 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
121 schema:familyName Webster
122 schema:givenName L. K.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062315554.40
124 rdf:type schema:Person
125 sg:person.01075643161.66 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
126 schema:familyName Millward
127 schema:givenName Michael J.
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075643161.66
129 rdf:type schema:Person
130 sg:person.01164010625.72 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
131 schema:familyName Urch
132 schema:givenName Maureen E.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164010625.72
134 rdf:type schema:Person
135 sg:person.01261320737.46 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
136 schema:familyName Woodcock
137 schema:givenName David M.
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261320737.46
139 rdf:type schema:Person
140 sg:person.01270354677.50 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
141 schema:familyName Rischin
142 schema:givenName Danny
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270354677.50
144 rdf:type schema:Person
145 sg:person.0776211666.91 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
146 schema:familyName Linsenmeyer
147 schema:givenName Martha E.
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776211666.91
149 rdf:type schema:Person
150 https://www.grid.ac/institutes/grid.1055.1 schema:alternateName Peter MacCallum Cancer Centre
151 schema:name Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrews Place, East Melbourne, Victoria, Australia 3002, AU
152 Division of Research, Peter MacCallum Cancer Institute, Locked Bag No. 1, A’Beckett Street, Melbourne, VIC, Australia 3000 Tel.+61-3-9656-1275; Fax+61-3-9656-1411; E-mail lwebster@petermac.unimelb.edu.au, AU
153 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...